Effect of exogenous surfactant (Calfactant) in pediatric acute lung injury - A randomized controlled trial

被引:289
作者
Willson, DF
Thomas, NJ
Markovitz, BP
Bauman, LA
DiCarlo, JV
Pon, S
Jacobs, BR
Jefferson, LS
Conaway, MR
Egan, EA
机构
[1] Univ Virginia Hlth Syst, Dept Pediat, Charlottesville, VA USA
[2] Penn State Univ, Dept Pediat, Hershey, PA USA
[3] Washington Univ, Dept Pediat, St Louis, MO 63130 USA
[4] Wake Forest Univ, Baptist Med Ctr, Dept Pediat, Winston Salem, NC 27109 USA
[5] Stanford Univ, Sch Med, Dept Pediat, Palo Alto, CA 94304 USA
[6] Cornell Univ, Weill Med Coll, Dept Pediat, New York, NY USA
[7] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH USA
[8] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA
[9] SUNY Buffalo, Dept Pediat, Buffalo, NY 14260 USA
[10] ONY Inc, Amherst, NY USA
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2005年 / 293卷 / 04期
关键词
D O I
10.1001/jama.293.4.470
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context Despite evidence that patients with acute lung injury (ALI) have pulmonary surfactant dysfunction, trials of several surfactant preparations to treat adults with ALI have not been successful. Preliminary studies in children with ALI have shown that instillation of a natural lung surfactant (calfactant) containing high levels of surfactant-specific protein B may be beneficial. Objective To determine if endotracheal instillation of calfactant in infants, children, and adolescents with ALI would shorten the course of respiratory failure. Design, Setting, and Patients A multicenter, randomized, blinded trial of calfactant compared with placebo in 153 infants, children, and adolescents with respiratory failure from ALI conducted from July 2000 to July 2003. Twenty-one tertiary care pediatric intensive care units participated. Entry criteria included age 1 week to 21 years, enrollment within 48 hours of endotracheal intubation, radiological evidence of bilateral lung disease, and an oxygenation index higher than 7. Premature infants and children with preexisting lung, cardiac, or central nervous system disease were excluded. Intervention Treatment with intratracheal instillation of 2 doses of 80 mL/m(2) calfactant or an equal volume of air placebo administered 12 hours apart. Main Outcome Measures Ventilator-free days and mortality; secondary outcome measures were hospital course, adverse events, and failure of conventional mechanical ventilation. Results The calfactant group experienced an acute mean (SD) decrease in oxygenation index from 20 (12.9) to 13.9 (9.6) after 12 hours compared with the placebo group's decrease from 20.5 (14.7) to 15.1 (9.0) (P=.01). Mortality was significantly greater in the placebo group compared with the calfactant group (27/75 vs 15/77; odds ratio, 2.32; 95% confidence interval, 1.15-4.85), although ventilator-free days were not different. More patients in the placebo group did not respond to conventional mechanical ventilation. There were no differences in long-term complications. Conclusions Calfactant acutely improved oxygenation and significantly decreased mortality in infants, children, and adolescents with ALI although no significant decrease in the course of respiratory failure measured by duration of ventilator therapy, intensive care unit, or hospital stay was observed.
引用
收藏
页码:470 / 476
页数:7
相关论文
共 28 条
[1]   Aerosolized surfactant in adults with sepsis-induced acute respiratory distress syndrome [J].
Anzueto, A ;
Baughman, RP ;
Guntupalli, KK ;
Weg, JG ;
Wiedemann, HP ;
Raventos, AA ;
Lemaire, F ;
Long, W ;
Zaccardelli, DS ;
Pattishall, EN .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (22) :1417-1421
[2]  
ASHBAUGH DG, 1967, LANCET, V2, P319
[3]   SURFACE PROPERTIES IN RELATION TO ATELECTASIS AND HYALINE MEMBRANE DISEASE [J].
AVERY, ME ;
MEAD, J .
AMA JOURNAL OF DISEASES OF CHILDREN, 1959, 97 (05) :517-523
[4]   THE AMERICAN-EUROPEAN CONSENSUS CONFERENCE ON ARDS - DEFINITIONS, MECHANISMS, RELEVANT OUTCOMES, AND CLINICAL-TRIAL COORDINATION [J].
BERNARD, GR ;
ARTIGAS, A ;
BRIGHAM, KL ;
CARLET, J ;
FALKE, K ;
HUDSON, L ;
LAMY, M ;
LEGALL, JR ;
MORRIS, A ;
SPRAGG, R ;
COCHIN, B ;
LANKEN, PN ;
LEEPER, KV ;
MARINI, J ;
MURRAY, JF ;
OPPENHEIMER, L ;
PESENTI, A ;
REID, L ;
RINALDO, J ;
VILLAR, J ;
VANASBECK, BS ;
DHAINAUT, JF ;
MANCEBO, J ;
MATTHAY, M ;
MEYRICK, B ;
PAYEN, D ;
PERRET, C ;
FOWLER, AA ;
SCHALLER, MD ;
HUDSON, LD ;
HYERS, T ;
KNAUS, W ;
MATTHAY, R ;
PINSKY, M ;
BONE, RC ;
BOSKEN, C ;
JOHANSON, WG ;
LEWANDOWSKI, K ;
REPINE, J ;
RODRIGUEZROISIN, R ;
ROUSSOS, C ;
ANTONELLI, MA ;
BELOUCIF, S ;
BIHARI, D ;
BURCHARDI, H ;
LEMAIRE, F ;
MONTRAVERS, P ;
PETTY, TL ;
ROBOTHAM, J ;
ZAPOL, W .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1994, 149 (03) :818-824
[5]   Incidence and mortality of acute lung injury and the acute respiratory distress syndrome in three Australian states [J].
Bersten, AD ;
Edibam, C ;
Hunt, T ;
Moran, J .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2002, 165 (04) :443-448
[6]   Nonparametric estimation in a cure model with random cure times [J].
Betensky, RA ;
Schoenfeld, DA .
BIOMETRICS, 2001, 57 (01) :282-286
[7]   Of Infasurf (calf lung surfactant extract) to Survanta (Beractant) in the treatment and prevention of respiratory distress syndrome [J].
Bloom, BT ;
Kattwinkel, J ;
Hall, RT ;
Delmore, PM ;
Egan, EA ;
Trout, JR ;
Malloy, MH ;
Brown, DR ;
Holzman, IR ;
Coghill, CH ;
Carlo, WA ;
Pramanik, AK ;
McCaffree, MA ;
Toubas, PL ;
Laudert, S ;
Gratny, LL ;
Weatherstone, KB ;
Seguin, JH ;
Willett, LD ;
Gutcher, GR ;
Mueller, DH ;
Topper, WH .
PEDIATRICS, 1997, 100 (01) :31-38
[8]   TARGETED DISRUPTION OF THE SURFACTANT PROTEIN-B GENE DISRUPTS SURFACTANT HOMEOSTASIS, CAUSING RESPIRATORY-FAILURE IN NEWBORN MICE [J].
CLARK, JC ;
WERT, SE ;
BACHURSKI, CJ ;
STAHLMAN, MT ;
STRIPP, BR ;
WEAVER, TE ;
WHITSETT, JA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (17) :7794-7798
[9]   Is outcome from ARDS related to the severity of respiratory failure? [J].
Ferring, M ;
Vincent, JL .
EUROPEAN RESPIRATORY JOURNAL, 1997, 10 (06) :1297-1300
[10]   Bovine surfactant therapy for patients with acute respiratory distress syndrome [J].
Gregory, TJ ;
Steinberg, KP ;
Spragg, R ;
Gadek, JE ;
Hyers, TM ;
Longmore, WJ ;
Moxley, MA ;
Cai, GZ ;
Hite, RD ;
Smith, RM ;
Hudson, LD ;
Crim, C ;
Newton, P ;
Mitchell, BR ;
Gold, AJ .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1997, 155 (04) :1309-1315